CCXI のPB 比率は同業他社と比較してどうか。

CCXIは、同業他社の平均 ( { 15.8 x) と比較したPrice-To-Book比率 ( 4.7 x) に基づいて高価です。

CCXI'のPB レシオは、US Biotechs 業界の他社と比較してどうか。

CCXIは、 US Biotechs業界平均 (1.9x) (15.8 x) と比較すると、 Price-To-Book比率 ( 1.9 x) に基づくと高価です。

CCXI'のPB レシオとフェアPB レシオを比較すると？これは、会社の予想利益成長率、利益率、その他のリスク要因を考慮した予想PB レシオです。

評価分析のためのCCXIのPrice-To-Book公正比率を計算するにはデータが不十分です。

CCXI 、その将来キャッシュフローを見たときの公正価格はいくらになるだろうか？この見積もりには、割引キャッシュフローモデルを使用します。

CCXI ( $51.99 ) は、当社の [[公正価値]] ( $137.89 ) の見積もりを下回って取引されています。

アナリストの12ヶ月の予想と、コンセンサス目標株価に対する統計的信頼性は？

価格予測を表示するにはデータが不十分です。

ChemoCentryx ( ) - 株価, ニュースと分析Nasdaq:CCXI

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

CCXI 株式概要

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States.

会社概要

CCXI ファンダメンタル分析
スノーフレーク・スコア
評価	2/6
将来の成長	5/6
過去の実績	0/6
財務の健全性	4/6
配当金	0/6

報酬

当社が推定した公正価値より62.3%で取引されている

収益は年間69.08%増加すると予測されています

リスク分析

過去3か月間の株価の変動は非常に激しい

過去1年間で株主の希薄化が進んだ

ChemoCentryx, Inc. 競合他社

Cerevel Therapeutics Holdings

NasdaqCM:CERE

US$8.2b

Nuvalent

NasdaqGS:NUVL

US$6.7b

CRISPR Therapeutics

NasdaqGM:CRSP

US$4.7b

Krystal Biotech

NasdaqGS:KRYS

US$5.6b

価格と性能

の歴代最高値、変動、値下がりまとめChemoCentryx
過去の株価
現在の株価	US$51.99
52週高値	US$52.00
52週安値	US$14.95
ベータ	1.23
11ヶ月の変化	0.41%
3ヶ月変化	134.51%
1年変化	50.39%
33年間の変化	558.10%
5年間の変化	642.71%
IPOからの変化	372.64%

ChemoCentryx shareholders approve $4.7B merger with Amgen

Oct 18

ChemoCentryx GAAP EPS of -$0.44 misses by $0.03, revenue of $11.76M misses by $9.89M

Aug 09

Recent updates

ChemoCentryx shareholders approve $4.7B merger with Amgen

Oct 18

ChemoCentryx GAAP EPS of -$0.44 misses by $0.03, revenue of $11.76M misses by $9.89M

Aug 09

Analysts Are Betting On ChemoCentryx, Inc. (NASDAQ:CCXI) With A Big Upgrade This Week

Jan 21

Checking In On ChemoCentryx

Dec 15

Is ChemoCentryx (NASDAQ:CCXI) Using Debt In A Risky Way?

Oct 09

ChemoCentryx: Make Or Break PDUFA Date For Avacopan May Not Go The Company's Way

Sep 29

ChemoCentryx And Avacopan In ANCA-Associated Vasculitis: Making Amends

Aug 24

Time To Worry? Analysts Just Downgraded Their ChemoCentryx, Inc. (NASDAQ:CCXI) Outlook

Aug 11

ChemoCentryx: CRL Less Likely

Jul 25

ChemoCentryx, Inc.'s (NASDAQ:CCXI) Intrinsic Value Is Potentially 34% Above Its Share Price

Jul 11

ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Jun 15

ChemoCentryx reports avacopan in ANCA vasculitis at ERA-EDTA congress

Jun 08

ChemoCentryx: CRL Likely

May 09

ChemoCentryx downgraded on narrow Adcom backing, Tilray jumps on double upgrade; in today’s analyst action

May 07

Chemocentryx shares plunge 47% as FDA report identifies concerns with vasculitis candidate

May 04

When Will ChemoCentryx, Inc. (NASDAQ:CCXI) Become Profitable?

Mar 03

ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Feb 04

ChemoCentryx: Great Drug, Good Prospects, Uncomfortable Stock Price

Jan 14

Have ChemoCentryx, Inc. (NASDAQ:CCXI) Insiders Been Selling Their Stock?

Dec 31

Analyst Forecasts Just Became More Bearish On ChemoCentryx, Inc. (NASDAQ:CCXI)

Dec 23

ChemoCentryx's avacopan flunks mid-stage study in rare kidney disease study

Dec 21

Did The Underlying Business Drive ChemoCentryx's (NASDAQ:CCXI) Lovely 934% Share Price Gain?

Dec 13

Are Investors Undervaluing ChemoCentryx, Inc. (NASDAQ:CCXI) By 25%?

Nov 22

ChemoCentryx, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 10

株主還元

	CCXI	US Biotechs	US 市場
7D	0.1%	-1.3%	3.9%
1Y	50.4%	22.8%	33.2%

業界別リターン: CCXI過去 1 年間で22.8 % の収益を上げたUS Biotechs業界を上回りました。

リターン対市場: CCXI過去 1 年間で33.2 % の収益を上げたUS市場を上回りました。

価格変動

Is CCXI's price volatile compared to industry and market?
CCXI volatility
CCXI Average Weekly Movement	31.3%
Biotechs Industry Average Movement	9.7%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.4%
10% least volatile stocks in US Market	3.0%

安定した株価: CCXIの株価は過去 3 か月間にわたって変動しています。

時間の経過による変動: CCXIの週次ボラティリティは、過去 1 年間で18%から31%に増加しました。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
1996	178	n/a	www.chemocentryx.com

ChemoCentryx, Inc. 基礎のまとめ

ChemoCentryx の収益と売上を時価総額と比較するとどうか。
CCXI 基礎統計学
時価総額	US$3.74b
収益（TTM）	-US$133.09m
売上高(TTM)	US$37.28m

100.3x

P/Sレシオ

-28.1x

PER（株価収益率

CCXI は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
CCXI 損益計算書（TTM）
収益	US$37.28m
売上原価	US$71.86m
売上総利益	-US$34.58m
その他の費用	US$98.51m
収益	-US$133.09m

直近の収益報告

Jun 30, 2022

次回決算日

該当なし

一株当たり利益（EPS）	-1.85
グロス・マージン	-92.76%
純利益率	-357.01%
有利子負債／自己資本比率	10.5%

CCXI の長期的なパフォーマンスは？

過去の実績と比較を見る

This company listing is no longer active

CCXI 株式概要

報酬

リスク分析

ChemoCentryx, Inc. 競合他社

NasdaqCM:CERE

US$8.2b

NasdaqGS:NUVL

US$6.7b

NasdaqGM:CRSP

US$4.7b

NasdaqGS:KRYS

US$5.6b

価格と性能

最新ニュース

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of ChemoCentryx, Inc. (NasdaqGS:CCXI) from a group of shareholders.

Chemocentryx, Inc. Announces Executive Changes

ChemoCentryx shareholders approve $4.7B merger with Amgen

Executive VP exercised options and sold US$798k worth of stock

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

ChemoCentryx GAAP EPS of -$0.44 misses by $0.03, revenue of $11.76M misses by $9.89M

Recent updates

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of ChemoCentryx, Inc. (NasdaqGS:CCXI) from a group of shareholders.

Chemocentryx, Inc. Announces Executive Changes

ChemoCentryx shareholders approve $4.7B merger with Amgen

Executive VP exercised options and sold US$798k worth of stock

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

ChemoCentryx GAAP EPS of -$0.44 misses by $0.03, revenue of $11.76M misses by $9.89M

Founder notifies of intention to sell stock

Price target decreased to US$54.29

Amgen Inc. (NasdaqGS:AMGN) entered into a definitive agreement to acquire ChemoCentryx, Inc. (NasdaqGS:CCXI) for $3.7 billion.

ChemoCentryx, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Chemocentryx, Inc. Announces Appointment of Jennifer L. Herron to Board as Independent Director

ChemoCentryx: Revisiting The Investment Case

Independent Director notifies of intention to sell stock

ChemoCentryx, Inc. Appoints Yi Ching Yau as Senior Vice President, Finance and Principal Accounting Officer

Chemocentryx Inc. Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered Pd-L1 Inhibitor, Ccx559, At the 2022 American Society of Clinical Oncology (Asco) Annual Meeting

ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?

ChemoCentryx Announces Changes to its Board of Directors

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Independent Director exercised options to buy US$212k worth of stock.

Insufficient new directors

ChemoCentryx, Inc. Reports Pharmacokinetic and Pharmacodynamic Results from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, Ccx559, At American Association for Cancer Research (Aacr) Annual Meeting 2022

ChemoCentryx, Inc., Annual General Meeting, May 26, 2022

Insufficient new directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

ChemoCentryx: Good Post-Approval Performance, But Needs More Time

Consensus revenue estimates fall by 13%

ChemoCentryx, Inc. to Report Q4, 2021 Results on Mar 01, 2022

ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?

Independent Director exercised options to buy US$905k worth of stock.

Analysts Are Betting On ChemoCentryx, Inc. (NASDAQ:CCXI) With A Big Upgrade This Week

ChemoCentryx, Inc Announces EU Approval of Tavneos® (Avacopan) for the Treatment of ANCA-Associated Vasculitis

Consensus revenue estimates fall by 13%

Founder exercised options and sold US$1.7m worth of stock

Forecast to breakeven in 2024

Independent Director exercised options and sold US$817k worth of stock

Checking In On ChemoCentryx

Founder exercised options to buy US$1.6m worth of stock.

Third quarter 2021 earnings released: US$0.32 loss per share (vs US$0.35 loss in 3Q 2020)

Is ChemoCentryx (NASDAQ:CCXI) Using Debt In A Risky Way?

Price target increased to US$68.43

ChemoCentryx: Make Or Break PDUFA Date For Avacopan May Not Go The Company's Way

ChemoCentryx Announces Approval in Japan of TAVNEOS™ (Avacopan) for the Treatment of ANCA-Associated Vasculitis

ChemoCentryx And Avacopan In ANCA-Associated Vasculitis: Making Amends

Second quarter 2021 earnings released: US$0.56 loss per share (vs US$0.32 profit in 2Q 2020)

Time To Worry? Analysts Just Downgraded Their ChemoCentryx, Inc. (NASDAQ:CCXI) Outlook

Consensus forecasts updated

ChemoCentryx: CRL Less Likely

ChemoCentryx, Inc.'s (NASDAQ:CCXI) Intrinsic Value Is Potentially 34% Above Its Share Price

Rosen Law Firm Encourages ChemoCentryx, Inc. Investors with Losses to Secure Counsel Before Important July 6, 2021 Deadline in Securities Class Action

ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

ChemoCentryx reports avacopan in ANCA vasculitis at ERA-EDTA congress

Kessler Topaz Meltzer & Check, LLP Announces Securities Fraud Class Action Lawsuit Filed against ChemoCentryx, Inc

Executive VP & COO recently bought US$120k worth of stock

Consensus revenue estimates fall to US$38.2m

ChemoCentryx: CRL Likely

ChemoCentryx Announces Results of U.S. Food and Drug Administration Advisory Committee Meeting on Avacopan in ANCA-Associated Vasculitis

Price target decreased to US$78.75